Skip to content


Takhzyro (lanadelumab) is an antibody pharmaceutical. Lanadelumab was first approved as Takhzyro on 2018-08-23. It has been approved in Europe to treat hereditary angioedemas. The pharmaceutical is active against plasma kallikrein.
Trade Name Takhzyro
Common Name Lanadelumab
Indication hereditary angioedemas
Drug Class Monoclonal antibodies: fully human, immunomodulating
Get full access now